Physicians must contemplate whether or not their individuals with underlying NAION threat components might be adversely afflicted by utilization of PDE5 inhibitors. Individuals who have already skilled NAION are at enhanced possibility of NAION recurrence. As a result, PDE5 inhibitors, which includes LEVITRA, need to be utilised with caution in the